Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Viktoria Blumenberg

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Blood Advances|June 26, 2026
Navigating clinical decision-making for IEC-enterocolitisViktoria Blumenberg, Mark B Leick
Nature Medicine|August 30, 2024
Tracking non-relapse mortality after CAR T cell therapyViktoria Blumenberg, Marcela V Maus
Blood|March 12, 2026
When CAR T cells become the diseaseViktoria Blumenberg, Marcela V Maus
Deutsche Medizinische Wochenschrift (1946)|August 27, 2021
[Practical aspects of the application of CAR T cells and management of their toxicities]Veit Bücklein, Viktoria Blumenberg, Marion Subklewe
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 22, 2025
Predictive value of maximum tumor dissemination (Dmax) in lymphoma patients treated with CD19-specific CAR T-CellsMichael Winkelmann, Philipp Achhammer, Viktoria Blumenberg, et al.
Hemasphere|October 3, 2022
Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall SurvivalMichael Winkelmann, Kai Rejeski, Viktoria Blumenberg, et al.
Frontiers in Oncology|September 26, 2022
Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessmentMichael Winkelmann, Veit L Bücklein, Viktoria Blumenberg, et al.
Cancer Treatment and Research Communications|January 7, 2026
Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapyChristina Quell, Wolfgang G Kunz, Viktoria Blumenberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 13, 2022
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|May 15, 2023
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteriaMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Blood Advances|June 26, 2026
Navigating clinical decision-making for IEC-enterocolitisViktoria Blumenberg, Mark B Leick
Nature Medicine|August 30, 2024
Tracking non-relapse mortality after CAR T cell therapyViktoria Blumenberg, Marcela V Maus
Blood|March 12, 2026
When CAR T cells become the diseaseViktoria Blumenberg, Marcela V Maus
Deutsche Medizinische Wochenschrift (1946)|August 27, 2021
[Practical aspects of the application of CAR T cells and management of their toxicities]Veit Bücklein, Viktoria Blumenberg, Marion Subklewe
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 22, 2025
Predictive value of maximum tumor dissemination (Dmax) in lymphoma patients treated with CD19-specific CAR T-CellsMichael Winkelmann, Philipp Achhammer, Viktoria Blumenberg, et al.
Hemasphere|October 3, 2022
Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall SurvivalMichael Winkelmann, Kai Rejeski, Viktoria Blumenberg, et al.
Frontiers in Oncology|September 26, 2022
Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessmentMichael Winkelmann, Veit L Bücklein, Viktoria Blumenberg, et al.
Cancer Treatment and Research Communications|January 7, 2026
Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapyChristina Quell, Wolfgang G Kunz, Viktoria Blumenberg, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 13, 2022
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|May 15, 2023
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteriaMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Pageof 5